Evidence map›Paper›PMID 36556453›Full record

ReviewLife (Basel, Switzerland)2022

HIV and SARS-CoV-2 Co-Infection: From Population Study Evidence to In Vitro Studies.

Chiara Stefani, Tobia Fantoni, Michele Bissoli, Jordan Thomas, Alessandra Ruggiero

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Chiara StefaniSection of Biology and Genetics, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.ORCID 0000-0003-2327-9772
Tobia FantoniSection of Biology and Genetics, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.ORCID 0000-0002-0594-1171
Michele BissoliSection of Biology and Genetics, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.ORCID 0000-0002-0904-6537
Jordan ThomasDepartment of Clinical Infection, Microbiology and Immunology, Institute of Veterinary and Ecological Sciences, University of Liverpool, Liverpool L69 3BX, UK.ORCID 0000-0003-2725-5233
Alessandra RuggieroSection of Biology and Genetics, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
University of Verona · ITUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human immunodeficiency virus type 1 (HIV-1) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused two major viral outbreaks during the last century. Two major aspects of HIV-1 and SARS-CoV-2 co-infection have been extensively investigated and deserve attention. First, the impact of the co-infection on the progression of disease caused by HIV-1 or SARS-CoV-2. Second, the impact of the HIV-1 anti-retroviral treatment on SARS-CoV-2 infection. In this review, we aim to summarize and discuss the works produced since the beginning of the SARS-CoV-2 pandemic ranging from clinical studies to in vitro experiments in the context of co-infection and drug development.

Indexed as

anti-retroviral drugsco-infectionsHIV-1SARS-CoV-2

Identifiers

PMID36556453
PMCPMC9781275
OpenAlexW4311387085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.